A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells.

abstract：:The prognostic importance of inhomogeneities on magnetic resonance imaging (MRI) in non-Hodgkin lymphomas (NHL) was evaluated. Forty-six consecutive patients with high-grade NHL were examined and, for comparison purposes, 13 patients with low-grade NHL. The degree of inhomogeneity was measured with a quantitative meth...

journal_title：Leukemia & lymphoma

authors： Rehn SM,Rodriguez M,Bergström SR,Nyman RS,Glimelius BL

更新日期：1997-02-01 00:00:00

abstract：:Considering conflicting data on CDKN2A/B deletion in ALL, this study to assess its prognostic significance as an independent marker in a total of 96 pediatric B and T-ALL cases was planned. The overall frequency of CDKN2A/B deletion was 44% (n = 43) with 36% (30/83) in B-ALL and 100% (13/13) in T-ALL. CDKN2A/B deletio...

journal_title：Leukemia & lymphoma

authors： Kathiravan M,Singh M,Bhatia P,Trehan A,Varma N,Sachdeva MS,Bansal D,Jain R,Naseem S

更新日期：2019-02-01 00:00:00

abstract：:This study evaluated whether measures of psychological well-being, including coping style, are associated with advance care planning (ACP). Data were from the Hematology Communications Study (HEMA-COMM), a prospective observational study of physician-patient communication in patients with hematologic malignancies. ACP...

journal_title：Leukemia & lymphoma

authors： Loberiza FR Jr,Swore-Fletcher BA,Block SD,Back AL,Goldman RE,Tulsky JA,Lee SJ

更新日期：2011-12-01 00:00:00

abstract：:The prognostic significance of specific cytogenetic abnormalities in follicular lymphoma (FL) is an area of ongoing research. A small percentage of FL are characterized by a polyploid karyotype. Several studies have analyzed ploidy level to determine its role as an independent prognostic factor in non-Hodgkins lymphom...

journal_title：Leukemia & lymphoma

authors： James GK,Horsman D,Connors JM,Klasa R,Wilson K,Argatoff L,Gascoyne RD

更新日期：1998-01-01 00:00:00

abstract：:HMG-CoA Reductase inhibitors (statins) induce apoptosis in acute myeloid leukemia (AML) cells in vitro; however, the concentrations associated with cell death in AML cells are higher than those clinically tolerated during prolonged therapy. We therefore wished to determine whether short exposures to lovastatin might i...

journal_title：Leukemia & lymphoma

authors： Burke LP,Kukoly CA

更新日期：2008-02-01 00:00:00

abstract：:The distribution of subtypes of non-Hodgkin lymphoma (NHL) in Latin America is not well known. This Chilean study included 207 consecutive cases of NHL diagnosed at five cancer centers in the capital, Santiago, and one center in Viña del Mar. All cases were reviewed and classified independently by five expert hematopa...

journal_title：Leukemia & lymphoma

authors： Cabrera ME,Martinez V,Nathwani BN,Muller-Hermelink HK,Diebold J,Maclennan KA,Armitage J,Weisenburger DD

更新日期：2012-07-01 00:00:00

abstract：:Four patients less than 20 years of age with Hodgkin's disease, who had developed either second or third relapse, were treated with high-dose chemotherapy followed by peripheral blood stem cell transplantation (PBSCT). Peripheral blood stem cells (PBSC) were collected after the administration of high-dose cytosine ara...

journal_title：Leukemia & lymphoma

authors： Matsuzaki A,Okamura J,Nagatoshi Y,Kai T,Ohga S,Gondo H,Inaba S,Ueda K

更新日期：1995-08-01 00:00:00

abstract：:Triptolide is a diterpenoid triepoxide purified from a Chinese herb Tripterygium Wilfordii Hook F (TWHF). TWHF has been used in traditional Chinese medicine for more than two thousand years. However, its potential value was recognized by the western medicine only after investigators observed the effectiveness of TWHF ...

journal_title：Leukemia & lymphoma

authors： Chen BJ

更新日期：2001-07-01 00:00:00

abstract：:Expression of T, sialosyl-T and disialosyl-T antigens on normal blood and bone marrow cells as well as transformed cells was examined using specific monoclonal antibodies and multidimensional flow cytometry. Both anti-sialosyl-T (QSH1) and anti-disialosyl-T (QSH2) monoclonal antibodies aggregated erythrocytes. The ant...

journal_title：Leukemia & lymphoma

authors： Muroi K,Amemiya Y,Sievers EL,Miura Y,Hakamori SI,Loken MR

更新日期：1997-05-01 00:00:00

abstract：:Ninety-nine patients with "standard risk" Stage IA-IIA Hodgkin's disease observed between January 1983 and December 1990, received radiotherapy only. The complete response rate was 98% (97/99). Twenty-one patients (21%) relapsed, 17 of whom (81%) obtained a second complete remission. The projected 9-year overall survi...

journal_title：Leukemia & lymphoma

authors： Zinzani PL,Barbieri E,Gherlinzoni F,Frezza G,Mazza P,Pica A,Ammendolia I,Bendandi M,Neri S,Miniaci G

更新日期：1994-04-01 00:00:00

abstract：:Human mantle cell lymphoma (MCL) cell lines are scarce and have been only sporadically described and validated, and only a few have been thoroughly molecularly or genetically characterized. We describe here the successful establishment of a new MCL line, PF-1, with typical MCL characteristics. Culturing primary MCL ce...

journal_title：Leukemia & lymphoma

authors： Pham LV,Vang MT,Tamayo AT,Lu G,Challagundla P,Jorgensen JL,Rollo AA,Ou Z,Zhang L,Wang M,Ford RJ

更新日期：2015-01-01 00:00:00

abstract：:Interdigitating dendritic cell sarcoma (IDCS) is an aggressive neoplasm of which fewer than 25 cases have been reported in the world literature. This malignancy is difficult to diagnose because of its rarity, and because of the subtle histopathologic features that distinguish IDCS from similar tumors arising from reti...

journal_title：Leukemia & lymphoma

authors： Olnes MJ,Nicol T,Duncan M,Bohlman M,Erlich R

更新日期：2002-04-01 00:00:00

abstract：:The purpose of this study was to explore lymphocyte subsets of newly diagnosed DLBCL patients, and dynamics along with treatment of R-CHOP. A total of 40 DLBCL patients were enrolled. ALC of grade III-IV DLBCL patients was significantly lower than that of health controls (1.33*10E9/L vs 1.89*10E9/L, p = 0.003), mostly...

journal_title：Leukemia & lymphoma

authors： Yang Z,Yu W,Wang S,Zhou X,Liu S,Ma S

更新日期：2019-12-01 00:00:00

abstract：:Patients with multiple myeloma who are refractory or intolerant to both bortezomib and lenalidomide have a poor prognosis. Next-generation therapies carfilzomib and pomalidomide have shown promising activity in this dual refractory population. Here we describe the clinical characteristics and ascertain the effects of ...

journal_title：Leukemia & lymphoma

authors： Wang TF,Ahluwalia R,Fiala MA,Trinkaus KM,Cox DP,Jaenicke M,Moliske CC,Carson KR,Wildes TM,Tomasson MH,Stockerl-Goldstein KE,Vij R

更新日期：2014-02-01 00:00:00

abstract：:Chronic lymphocytic leukemia (CLL) is a neoplastic disorder of mature B lymphocytes. While traditionally treated with combinations of chemoimmunotherapy, the therapeutic options for CLL have expanded in recent years with the emergence of novel oral agents, such as the Bruton tyrosine kinase inhibitor ibrutinib, that a...

journal_title：Leukemia & lymphoma

authors： Piggin A,Bayly E,Tam CS

更新日期：2017-06-01 00:00:00

abstract：:The association of chronic lymphocytic leukemia (CLL) with essential thrombocythemia (ET) is an extremely rare event and until now 3 patients with such coexistence have been reported in the literature. We report a 77-year-old white woman in whom these two disorders were diagnosed concomitantly on the basis of peripher...

journal_title：Leukemia & lymphoma

authors： Robak T,Urbańska-Ryś H,Góra-Tybor J,Wawrzyniak E,Korycka A,Bartkowiak J,Kordek R,Polliack A

更新日期：2003-08-01 00:00:00

abstract：:The tyrosine kinase inhibitors (TKIs), nilotinib, ponatinib, and dasatinib (but not bosutinib or imatinib), are associated with vascular adverse events (VAEs) in chronic myeloid leukemia (CML). Though the mechanism is inadequately understood, an effect on vascular cells has been suggested. We investigated the effect o...

journal_title：Leukemia & lymphoma

authors： Gover-Proaktor A,Granot G,Pasmanik-Chor M,Pasvolsky O,Shapira S,Raz O,Raanani P,Leader A

更新日期：2019-01-01 00:00:00

abstract：:Follicular lymphoma is an indolent and usually incurable disease. It has been, therefore, traditionally approached either by watch and wait or with single-agent treatments with the purpose of maintaining a good quality of life for a prolonged time. The emergence of more aggressive regimens including polychemotherapy, ...

journal_title：Leukemia & lymphoma

authors： Feuerlein K,Zucca E,Ghielmini M

更新日期：2009-03-01 00:00:00

abstract：:Analysis of leukemia-specific and leukemia-associated markers following standard or high-dose treatments is crucial in order to evaluate the efficacy of therapeutic strategies. During the last decade, several techniques have been proposed and used for detecting minimal residual disease (MRD). Each approach is characte...

journal_title：Leukemia & lymphoma

authors： Carlo-Stella C,Mangoni L,Dotti GP,Rizzoli V

更新日期：1995-01-01 00:00:00

abstract：:Impressive gains have been made in the therapy of childhood acute lymphoblastic leukemia (ALL) in recent years such that remissions today are commonly achieved in up to 95% of patients and long term disease-free survival rates approach 70%. Methotrexate is a key component in ALL consolidation and maintenance therapies...

journal_title：Leukemia & lymphoma

authors： Matherly LH,Taub JW

更新日期：1996-05-01 00:00:00

abstract：:Relapse represents the main cause of treatment failure after allogeneic stem cell transplant (allo-SCT). The detection of minimal residual disease (MRD) by multiparametric flow cytometry (MFC), chimerism, cytogenetics and molecular analysis may be critical to prevent relapse. Therefore, we assessed the overall agreeme...

journal_title：Leukemia & lymphoma

authors： Rossi G,Carella AM,Minervini MM,Savino L,Fontana A,Pellegrini F,Greco MM,Merla E,Quarta G,Loseto G,Capalbo S,Palumbo G,Cascavilla N

更新日期：2013-12-01 00:00:00

abstract：:This retrospective study concerns non-bacterial infections in Asian patients receiving alemtuzumab. The clinical data of 182 patients treated with alemtuzumab alone or alemtuzumab-containing chemotherapy between the years 2003 and 2009 was collected from six Asian countries. Alemtuzumab was used in the setting of fron...

journal_title：Leukemia & lymphoma

authors： Kim SJ,Moon JH,Kim H,Kim JS,Hwang YY,Intragumtornchai T,Issaragrisil S,Kwak JY,Lee JJ,Won JH,Reksodiputro AH,Lim ST,Cheng AL,Kim WS,Kwong YL

更新日期：2012-08-01 00:00:00

abstract：:Neurological symptoms can represent the first clinical manifestation of central nervous system (CNS) involvement in Hodgkin lymphoma (HL). Because of its rarity, it is often misunderstood for other pathological processes. We report two cases of pediatric CNS HL, presenting with neurological symptoms at diagnosis. We h...

journal_title：Leukemia & lymphoma

authors： Burnelli R,Fabbri E,Guerrini G,Sperlì D,D'ambrosio A

更新日期：2011-06-01 00:00:00

abstract：:Systemic mast cell disease (SMCD) has a highly variable clinical expression and course. That SMCD is associated with hematologic disorders has been widely described. We report an unusual case of systemic mast cell disease and concurrent chronic myelomonocytic leukemia in a 60 year old male. ...

journal_title：Leukemia & lymphoma

authors： Smith JD,Lazarchick J

更新日期：1999-01-01 00:00:00

abstract：:In ninety-three cases of newly diagnosed acute myeloid leukaemia (AML) we investigated the importance to short- and long term clinical outcome of the in vitro short term leukaemia cell survival as measured by a 4-day MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide)-assay. In 67 patients treated by i...

journal_title：Leukemia & lymphoma

authors： Nørgaard JM,Jensen PD,Bendix K,Clausen N,Palshof T

更新日期：1999-01-01 00:00:00

abstract：:Multidrug resistance gene (mdr1) RNA levels were determined in 55, and P-glycoprotein expression in 37 samples of peripheral leukemic cells from 17 patients with acute myeloblastic leukemia (AML) and 7 patients with acute lymphocytic leukemia (ALL). Between sample collections, patients were treated with various chemot...

journal_title：Leukemia & lymphoma

authors： Gruber A,Areström I,Albertioni F,Björkholm M,Peterson C,Vitols S

更新日期：1995-08-01 00:00:00

abstract：:In this review, the role of angiogenic and lymphangiogenic growth factors in hematological malignancies is summarized, alongside with possible therapeutic applications. Recent data demonstrate the importance of angiogenesis in hematologic malignancies including leukemia, lymphoma, and multiple myeloma. Expression of a...

journal_title：Leukemia & lymphoma

authors： Orpana A,Salven P

更新日期：2002-02-01 00:00:00

abstract：:A 54-year-old man with chronic idiopathic myelofibrosis (CIMF) underwent RIST. His clinical course had been uneventful until day 60, when splenomegaly reappeared. Hepatic dysfunction developed on day 75. Recipient-type hematopoiesis increased to 51% on day 90. After rapid tapering of cyclosporin, serum levels of AST a...

journal_title：Leukemia & lymphoma

authors： Miyakoshi S,Kami M,Kishi Y,Murashige N,Yuji K,Kusumi E,Matsumura T,Onishi Y,Kobayashi K,Kim SW,Hamaki T,Takaue Y,Taniguchi S

更新日期：2004-12-01 00:00:00

abstract：:Interleukin-6 (IL-6) is the major growth factor for the malignant plasma cell clone in patients with multiple myeloma (MM). Although interferon-alpha (IFN-alpha) has been widely used as maintenance therapy in MM, controversy exists as to its clinical utility. This review summarizes data showing that cell growth arrest...

journal_title：Leukemia & lymphoma

authors： Hawley RG,Berger LC

更新日期：1998-05-01 00:00:00

abstract：:Tumour progression was monitored in seven multiple myeloma (MM) patients undergoing a novel oral chemotherapy regimen (cyclophosphamide, idarubicin and dexamethasone; CID) followed by early autologous stem cell transplantation (ASCT). Allele-specific oligonucleotide PCR (ASO-PCR) was used to semi-quantitate the number...

journal_title：Leukemia & lymphoma

authors： Lincz LF,Crooks RL,Way SL,Granter N,Spencer A

更新日期：2001-01-01 00:00:00